Johnson and Johnson's Resilient Performance and Positive Outlook for 2025

# Johnson & Johnson (JNJ) Stock Surges with Analyst Upgrades & Strategic Acquisitions In this episode, we analyze Johnson & Johnson's impressive stock performance as it closed at $207.56 on December 29, 2025, with notable analyst upgrades driving investor optimism. We break down Barclays' newly raised price target of $217, RBC Capital and Wells Fargo's bullish $230 targets, and what's behind JNJ's lighter-than-average trading volume during the holiday season. Discover how JNJ's strategic $3.05 billion acquisition of Halda Therapeutics is strengthening their prostate cancer therapy portfolio, plus recent FDA approvals expanding their medical device and oncology offerings. With remarkable growth in key pharmaceuticals like Darzalex (26%) and Tremfya (56%), we explore why analysts maintain a moderate buy consensus with a $211.25 target price. For income investors, we examine JNJ's attractive 2.5% dividend yield, current P/E ratio of 19.3, and Zacks' projected 6.41% earnings growth for 2025 - making this healthcare giant a compelling consideration for your portfolio during market uncertainty. Subscribe now for more expert stock analysis from Quiet Please. Visit quietplease.ai for additional market insights and investment strategies. #JohnsonAndJohnson #StockAnalysis #InvestmentStrategy #HealthcareStocks #DividendStocks #WallStreet #StockMarketAnalysis #Investing2025 For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.